Feedback / Questions
Skyrizi (risankizumab) - AbbVie, Boehringer Ingelheim
Skyrizi: Initiation of P3 trial for ulcerative colitis in 2020
(AbbVie)
-
Feb 8, 2020 -
Pipeline Update: Initiation of P3 trial for atopic dermatitis in 2021
New P3 trial
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
Feb 8, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious